Table 1.
Summary of FDA-approved anti-angiogenic agents
| Anti-angiogenic agents | Manufacturer | Target | Date of first FDA approval | Condition |
|---|---|---|---|---|
|
Bevacizumab (Avastin) |
Genentech | VEGF | 2004. 02 |
Metastatic colorectal cancer, non-squamous small cell lung cancer, cervical cancer, ovarian cancer, metastatic breast cancer, malignant glioma |
|
Ramucirumab (Cyramza) |
ImClone | VEGFR2 | 2014. 04 | Advanced gastric or gastroesophageal adenocarcinoma, non-small-cell lung cancer, and metastatic urinary tract epithelial cancer |
|
Ziv-aflibercept (Zaltrap) |
Sanofi | VEGFA/VEGFB /PIGF | 2012. 08 | Metastatic colorectal cancer |
|
Axitinib (Inlyta) |
Pfizer | VEGFR/KIT/PDGFR/RET/ CSF1R/FLT3 | 2012. 01 | Advanced renal cell carcinoma |
| Sorafenib (Nexavar) | Bayer | VEGFR2/PDGFR /KIT/FLT3/BRAF | 2005. 12 | Renal cell and hepatocellular carcinoma and thyroid cancer |
|
Sunitinib (Sutent) |
Pfizer | VEGFR/KIT /PDGFR | 2006. 01 | Gastrointestinal stromal tumors, advanced renal cancer, and metastatic well-differentiated advanced pancreatic neuroendocrine tumors |
|
Regorafenib (Stivqrga) |
Bayer | VEGFR/PDGFR /KIT/FGFR | 2012. 09 |
Metastatic colorectal cancer, gastrointestinal mesenchymal liver cancer |
|
Nintedanib (OFEV) |
Boehringer lngelheim |
VEGFR/PDGFR /FGFR | 2014. 10 | Idiopathic pulmonary fibrosis, non-small cell lung cancer |
|
Cabozantinib (Cabometyx) |
Exelixis | RET/VEGFR2 /PDGFR/KIT/FLT3/ MET/AXL | 2012. 11 | Metastatic thyroid cancer, non-small cell lung cancer with c-Met amplification |
|
Pazopanib (Votrient) |
GlaxoSmithKline |
VEGFR/PDGFR /KIT |
2009. 10 | Advanced renal cancer, advanced soft tissue sarcoma, epithelial ovarian cancer, non-small cell lung cancer |